syenfrout, the first line of your post is right on target. Definitely futile to try and predict a bottom, especially when so much hyperbole is being hurled around. In a week or so things will settle down.
It depends on what you mean by on the horizon. The final data for Galaxy 1 will be in in late fall. For other NSCLC trials, there is the SNTA sponsored phase II trial of Gatenespib in ALK+ patients, and the Memorial Sloan-Kettering sponsored phase I/II trial of Ganetespib + Crizotinib but the latter is in early stages. ALK is a client of HSP-90 so the chances for a good outcome are high. The Enchant phase II breast cancer trial is ongoing and the estimated primary completion date is Sept 2013. SNTA added a third arm, Ganetespib + paclitaxel earlier this year, so that arm might be later.